Efficacy of Helicobacter pylori eradication therapy in chronic liver disease

被引:15
作者
Jung, S. W. [1 ]
Lee, S. W. [1 ]
Hyun, J. J. [1 ]
Kim, D. I. [1 ]
Koo, J. S. [1 ]
Yim, H. J. [1 ]
Park, J. J. [1 ]
Lee, H. S. [1 ]
Chun, H. J. [1 ]
Um, S. H. [1 ]
Choi, J. H. [1 ]
Kim, C. D. [1 ]
Ryu, H. S. [1 ]
机构
[1] Korea Univ, Coll Med, Dept Internal Med, Div Gastroenterol,Ansan Hosp, Ansan 425707, Gyeonggi Do, South Korea
关键词
Chronic liver disease; Eradication rate; Helicobacter pylori; PEPTIC-ULCER-DISEASE; PORTAL HYPERTENSIVE GASTROPATHY; CIRRHOTIC-PATIENTS; GASTRIC-ULCER; INFECTION; EPIDEMIOLOGY; SEROPREVALENCE; PREVALENCE; RECURRENCE; ALCOHOL;
D O I
10.1016/j.dld.2008.03.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/aims. Peptic ulcers occur more commonly in patients with liver cirrhosis (LC). Helicobacter pylori is recognized as the most important etiology in the pathogenesis of peptic ulcers. We investigated the efficacy of proton pump inhibitor (PPI)-based triple therapy in patients with chronic liver disease and peptic ulcer. Patients and methods. One hundred sixty-three patients with LC or chronic hepatitis (CH) with a peptic ulcer and proven H. pylori infection were included. The combination of PPI, amoxicillin (1.0 g), and clarithromycin (500 mg), each given twice daily, was administered for I or 2 weeks. The eradication of H. pylori was determined by the rapid urease test, histology, or the C-13-urea breath test at least 4 weeks after completing the treatment. Results. The eradication rate of H. pylori was similar between the LC and CH groups; 82.6% and 88.1%, respectively. In addition, there were no significant differences in eradication rates between the patients with Child-Pugh class A and Child-Pugh class B/C disease. The side effects in each group were generally mild. Only the serum ALT levels showed a significant correlation with the success of H. pylori eradication in both the LC and CH groups. Conclusion. The PPI-based triple therapy achieves high eradication rates for H. pylori infection, in patients with chronic liver disease, without significant side effects. (C) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:134 / 140
页数:7
相关论文
共 29 条
[1]   Gastroduodenal ulcer and erosions are related to portal hypertensive gastropathy and recent alcohol intake in cirrhotic patients [J].
Auroux, J ;
Lamarque, D ;
Roudot-Thoraval, F ;
Deforges, L ;
Chaumette, MT ;
Richardet, JP ;
Delchier, JC .
DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (06) :1118-1123
[2]   Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis [J].
Azuma, T ;
Ito, S ;
Suto, H ;
Ito, Y ;
Miyaji, H ;
Yamazaki, Y ;
Kato, T ;
Kuriyama, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 :216-222
[3]   Helicobacter pylori:: Epidemiology and routes of transmission [J].
Brown, LM .
EPIDEMIOLOGIC REVIEWS, 2000, 22 (02) :283-297
[4]   Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis [J].
Calvet, X ;
Navarro, M ;
Gil, M ;
Mas, P ;
Rivero, E ;
Sanfeliu, I ;
Brullet, E ;
Campo, R ;
Dalmau, B ;
Lafont, A .
JOURNAL OF HEPATOLOGY, 1997, 26 (06) :1249-1254
[5]  
Calvet X, 1998, AM J GASTROENTEROL, V93, P2501, DOI 10.1111/j.1572-0241.1998.00711.x
[6]   ROLE OF HELICOBACTER-PYLORI IN CIRRHOTIC-PATIENTS WITH PEPTIC-ULCER - A SEROLOGICAL STUDY [J].
CHEN, JJ ;
CHANGCHIEN, CS ;
TAI, DI ;
CHIOU, SS ;
LEE, CM ;
KUO, CH .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (07) :1565-1568
[7]   Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension [J].
Chen, LS ;
Lin, HC ;
Hwang, SJ ;
Lee, FY ;
Hou, MC ;
Lee, SD .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1996, 11 (01) :59-64
[8]  
DIMARIO F, 1992, ITAL J GASTROENTEROL, V24, P122
[9]   Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis:: The role of Helicobacter pylori infection and portal hypertensive gastropathy [J].
Dore, MP ;
Mura, D ;
Deledda, S ;
Maragkoudakis, E ;
Pironti, A ;
Realdi, G .
CANADIAN JOURNAL OF GASTROENTEROLOGY, 2004, 18 (08) :521-524
[10]   DISPOSITION AND METABOLISM OF METRONIDAZOLE IN PATIENTS WITH LIVER-FAILURE [J].
FARRELL, G ;
BAIRDLAMBERT, J ;
CVEJIC, M ;
BUCHANAN, N .
HEPATOLOGY, 1984, 4 (04) :722-726